I. Executive Summary 5 II. Study Goal and Objectives 13 ...

1

Table of Contents

Page

I. Executive Summary 5II. Study Goal and Objectives 13III. Respondent Demographics 15IV. Use and Satisfaction 22V. Selection Criteria and Perceptions 30VI. Company Profiles 39

2

Preface

We have been conducting voice of the customer research in the eClinical platform space for more than a decade, watching customers migrate from early piecemeal solutions offered by larger clinical CROs to early standards such as Oracle Clinical. Enter Medidata with its Rave EDC and Clinical Cloud platform, which won over customers with a pure-play eClinical platform that became the de-facto market leader. Since then, several other eClinical platform providers have entered the space with several making significant inroads to the point that they are are challenging the market leader.

Given that we had not undertaken a large, market survey of customer perceptions of the leading eClinical providers in several years, we felt the timing was right to take a fresh look. We were anxious to see if Medidata was still at the forefront of customer perceptions for market leadership, vendor performance and satisfaction, or if other strong market competitors, like Veeva, IQVIA or Covance, had overtaken the leader with their solutions.

Upon digging into the data an interesting story emerges. The established market leader, while still firmly perceived to be as such, has a few clear “holes in its armor”. One vendor, in particular, is offering a platform solution that is resonating with customers through its intuitiveness and ease of use, to the point that we will be watching this market closely to see if a “passing of the market leadership torch” happens in the future.

The following report details customer perceptions of the leading eClinical platforms and providers across a multitude of vendor selection, performance and satisfaction metrics. We have analyzed the data from which the implications are clear. The Pharma industry is looking for eClinical platforms that guarantee the quality and integrity of its data while improving overall efficiency. The eClinical platform that delivers this to the market will be best positioned to succeed.

-Life Science Strategy Group, LLC

3

N=100

• More than 70 unique biopharmaceutical companies are represented by the research sample.

N=100

Respondent Demographics

Source: Life Science Strategy Group, LLC

Q. Where are you located?Q. Which BEST describes the type of company that you currently work for?Q. What activities are part of your current role as it relates to the decision-making process for procuring and or selecting an external provider for an eClinical Platform solution?

N=100

Location 18%

82%

0% 50% 100%% of Respondents

Pharma/Biotech Company

Size 29%

34%

37%

0% 10% 20% 30% 40%% of Respondents

North America

Europe

Mid-Size($300M to $1B R&D Spend)

Large (>$1B R&D Spend)

Small(<$300M R&D Spend)

78%19% 3%

0%

20%

40%

60%

80%

100%

% o

f Res

pond

ents

Part of a team or committee

Final decision maker

End user/Daily interaction with the external provider

Decision Influence

(% of Respondents)

(% of Respondents)

4

35% 63% 87% 85% 40%0%

20%40%60%80%

100%

% o

f Res

pond

ents

4% 16% 26% 54%

0%

20%

40%

60%

% o

f Res

pond

ents

N=100


Q. How many years combined have you been in your current and related roles?Q. Within what Phase(s) of drug development are you actively involved? Please select all that apply.Q. Please indicate your position level or equivalent.


N=100

1 to 3 yearsYears of

Experience

10%16%20%54%

0% 10% 20% 30% 40% 50% 60%% of Respondents

C-Suite

Vice PresidentSenior Director/Director/

Associate Director

PositionLevel

Senior Manager/ Manager/Associate Manager

4 to 7 years

8 to 15 years

More than 15 years

N=100

PreclinicalDrug

Discovery

Early Clinical(Phase I/IIa)

Phase(s) of Development Involvement

Post-approval/ Commercial

Late Clinical (Phase IIb/III)

5

N=100

Source: Life Science Strategy Group, LLCQ. What best describes your role in clinical development? Please select all that apply.


Role in Clinical Development

4%

8%

11%

12%

20%

20%

20%

25%

35%

35%

39%

56%

68%

0% 20% 40% 60% 80%

Other*

Commercial

IT/Technology

Principal Investigator

Biostatistics/Data Science/Analytics

Medical Affairs/Medical

Regulatory Affairs

Corporate Management/C-Suite

Trial Management

Sourcing/Procurement

Program Lead/Manager

Clinical Operations

Research and Development

% of Respondents

Other* includes: Data manager, QA, Systems and processes, Quality

6

72%10%

18%

0%

20%

40%

60%

80%%

of R

espo

nden

ts

N=100


Q. What best describes your company’s experience with eClinical platforms?Q. What best describes your interaction with an eClinical platform/provider?


N=100

eClinical platform being considered

eClinical platform currently in use

eClinical platform in implementation stageCompany

Experience with eClinical Platforms

21%

36%

43%

0% 10% 20% 30% 40% 50%% of Respondents

Involved in the purchasing decision, but not day-to-day use of an eClinical platform

Interaction with eClinical

Platform/Provider

Actively use eClinical platform(s) to manage clinical trials/programs

Manage/Implement clinical trial technologies

7

40% 40%

34%

28%25%

22%19%

17%

11% 10%7% 6% 5%

17%15%

20%

26%24%

27%

18%

26%

21%18%

15%

20%

8%

21%23%

26% 27%31%

34% 35%

27%

32%

37%

30% 30% 31%

13%16%

11% 12%16%

11%

17%21% 21%

25%22%

27%

11%9%

6%9%

7%4%

6%

11%9%

15%

10%

26%

17%

45%

0%

10%

20%

30%

40%

50%

% o

f Res

pond

ents

Currently using Used in the past 12-18 months, but NOT using todayFamiliar with and currently or previously considered, but never used Familiar with but never used or consideredNot aware of/Not familiar N=100

Source: Life Science Strategy Group, LLCQ. What best describes your status with each of the following eClinical platform providers/solutions? Please indicate for each provider.


Status with eClinical Platform Providers/Solutions

8Source: Life Science Strategy Group, LLC

Companies/eClinical Platforms Included in the Analysis and Profiled

• Almac Clinical Technologies• BioClinica Cloud• Covance Xcellerate• Emmes Advantage eClinical Suite• IBM Clinical Development• ICON Flex Advantage• IQVIA Infosario• Medidata Rave Clinical Cloud• Oracle Platform and Clinical One• Parexel Perceptive Cloud• PPD CTMS• PRA Health Prism eClinical Solution• Veeva Vault Clinical

9

Top eClinical platforms increase users’ productivity while providing a consistent user experience which allows faster, more efficient clinical trials. eClinical platforms are more attractive if they help companies reduce internal effort.

Source: Life Science Strategy Group, LLCQ. What are the top benefits or value propositions offered by an eClinical platform? Please select the top-3 options.

Top Benefits/Value Propositions Offered by an eClinical Platform

53%47% 44%

39%35% 33%

24% 23%

2%0%

10%

20%

30%

40%

50%

60%

70%

Increasinguser

productivity

Providing aconsistent

userexperiencewith cross-

productworkflows

Earlier trialinitiation andfaster patientenrollment

Streamliningissue andquestionresolution

Reducinglong-term

cost

Expeditinggo/no-godecisionmaking

Preventingoverextension

of internalresources

Regulatorymandates

Other*

% o

f Res

pond

ents

Other* includes: Real time insights for sponsor into study status, Ability to assure more timely database lock on study completion

N=100

Sample Pages


Q. What percent of your/your company’s clinical trials currently utilize each of the following eClinical platforms/providers as the primary solution?

eClinical Platform Share of Voice

YYY share of voice leads other providers in clinical trial utilization, followed closely by A, B and C.

1%

1%

2%

2%

4%

6%

7%

8%

8%

14%

14%

15%

18%

0% 5% 10% 15% 20%

Share of Voice N=100Note: Share of voice calculation involves percent utilization for all vendors from all respondents averaged across the full respondent sample.

Sam

ple

Page

s

11

12%12%

14%14%15%16%

21%23%

31%32%

34%34%

38%40%40%41%41%42%

0% 10% 20% 30% 40% 50%

Customer service/responsiveness/accessibilityPlatform performance/speed

Reputation of the eClinical platform providerCloud capabilities (e.g., access and administration)

Vendor's therapeutic/disease area expertiseInnovation (e.g., AI and machine learning)

Customizability/flexibilityPast experience with the eClinical platform provider

Speed and ease of implementationIntegration with existing/multiple eClinical systems

Ease of use/intuitiveRegulatory compliance

Data analytics, visualization, and reportingCost

Real-time access to dataReliability

Data securityData integrity/validation

Top Criteria Evaluated when Selecting an eClinical Platform

Top criteria evaluated when selecting an eClinical platform relate X, Y and Z.

Source: Life Science Strategy Group, LLCQ. What are the top-5 criteria evaluated when selecting an eClinical platform solution?

N=100

% of Respondents

Top criteria for mid-sized pharma

Top criteria for small pharma

Large (49%), mid-sized (28%) vs. small (7%)

Segmentation Differences

Small (45%) vs. large (22%)

Small (52%) vs. large (32%)

Sample Pages

12

Data integrity/validation

Data security

Real-time access to data

Data analytics, visualization, and reporting

Respondents perceive Veeva Vault Clinical as the top platform across several attributes, including data security, ease of use, regulatory compliance, and cloud capabilities.


Deep Dive Comparison – Platform Selection Criteria vs Perceived Vendor Performance

Data Quality, Access, & Analytics

Ease of use/intuitive

Speed and ease of implementation

Platform performance/speed

Platform Performance

& Ease of Use

Reliability

Regulatory compliance

Integration with eClinical systems

Customizability/flexibility

Innovation (e.g., AI and machine learning)

Cloud capabilities

Platform Capabilities

& Integration

Past experience w/eClinical platform provider

Vendor's therapeutic/disease area expertise

Reputation of the eClinical platform provider

Customer service/responsiveness/accessibility

Vendor Reputation & Expertise

Increasing Degree of High Satisfaction*±

*Top 2 Scores (% of respondents with a score of 7 and 6)±Sample sizes vary per attribute and some may be directional

Sample Pages

Sample Pages

Sample Pages


Company ProfileCompany X

Platform Strengths

BrandIndustry

Avg.Advocacyǂ (NPS) -29% -38%

Repeat Business* 36% 28%

Prefer* 42%▲ 30%

Consider* 44% 32%

Use (Current + Recent) 55% 40%

Unaided Awareness 37%▲ 14%

Aided Awareness 94% 87%

Platform Weaknesses

Performance on Important Platform Selection Criteria±Top 2 Scores*

Brand Performance% of Respondents

28% of respondents perceive XXX as the market leader

n=55†N=100

Perception as Market Leader

n=78

ⱡ Net Promoter Score*Top 2 Scores (% of respondents with a score of 7 and 6)▲Top performance among all platforms±Cumulation of various attributes; sample sizes vary per attribute

†Includes respondents currently using or recently used platform

N=1

00

Share of Voice: 18%

35%28%

63%

36%

16%31% 25%

36%30%

19%

Data Quality,Access, &Analytics

PlatformPeformance

& Ease of Use

PlatformCapabilities &

Integration

VendorReputation &

Expertise

Cost

Sample Pages

Sample Pages

I. Executive Summary 5 II. Study Goal and Objectives 13 ...

Documents